Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P63135
UPID:
POK7_HUMAN
Alternative names:
HERV-K(III) Pol protein; HERV-K102 Pol protein; HERV-K_1q22 provirus ancestral Pol protein
Alternative UPACC:
P63135
Background:
The Endogenous retrovirus group K member 7 Pol protein, known by alternative names such as HERV-K(III) Pol protein, HERV-K102 Pol protein, and HERV-K_1q22 provirus ancestral Pol protein, plays a crucial role in the early stages of viral infection. It is responsible for converting viral RNA into double-stranded DNA, a process facilitated by its reverse transcriptase and RNase H domain. This domain not only degrades the RNA template but also removes the RNA primer, paving the way for the integration of viral DNA into the host cell chromosome.
Therapeutic significance:
Understanding the role of Endogenous retrovirus group K member 7 Pol protein could open doors to potential therapeutic strategies.